⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 1, 2024Open Access

Figure S3 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts

Elyse A. Olesinski Karanpreet Singh Bhatia Chuqi Wang Marissa S. Pioso Xiao Xian Lin Ahmed M. Mamdouh Shu Xuan Ng Vedant Sandhu Shaista Shabbir Jasdanwala Binyam Yilma Stephan Bohl Jeremy Ryan Disha Malani Marlise R. Luskin Olli Kallioniemi Kimmo Porkka Sophia Adamia Wee Joo Chng Motomi Osato David M. Weinstock Jacqueline S. Garcia Anthony Letai Shruti Bhatt

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplemental Figure 3 shows MDR mechanisms contribute to drug resistance in AML PDX models.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Olesinski et al. (2024) studied this question.

synapsesocial.com/papers/68e6c4b3b6db643587643638 https://doi.org/10.1158/2643-3230.25728773.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S8 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts2024
2Figure S4 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts2024
3Figure S11 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts2024
4Figure S2 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts2024
5Figure S7 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts2024

Figure S6 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts2024
Table S1 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts2024
Table S1 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts2024